Sequential Dose-Dense Doxorubicin and Ifosfamide in Advanced Soft-Tissue Sarcoma Patients in an Out-Patient-Basis Schedule

<table>Overall survival according to immunohistochemical ezrin expression. Median overall survival for soft-tissue sarcomas patients whose tumors were classified as positive for ezrin was 21.1 months, compared to 8.6 months for ezrin-negative patients; HR 0.39, 95% CI 0.08–1.31; <svg height="10.8625" id="M14" style="vertical-align:-0.13794pt" version="1.1" viewbox="0 0 48.337502 10.8625" width="48.337502" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.8625)">
<g transform="translate(72,-63.31)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
<tspan style="font-size: 12.50px; " x="10.890113" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="22.930502" y="0">.</tspan>
<tspan style="font-size: 12.50px; " x="26.056252" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="32.307751" y="0">1</tspan>
</text>
</g>
</g>
</svg>.</table>

Sarcoma

fig2

Figure 2

Figure 2: Sequential Dose-Dense Doxorubicin and Ifosfamide in Advanced Soft-Tissue Sarcoma Patients in an Out-Patient-Basis Schedule 